

MORBIDITY AND MORTALITY

WEEKLY REPORT

- 677 Human Anthrax Associated With an Epizootic Among Livestock North Dakota, 2000
- Botulism Outbreak Associated 680 With Eating Fermented Food -Alaska, 2001
- 682 Self-Reported Asthma Prevalence Among Adults — United States, 2000 687
 - Notices to Readers

Human Anthrax Associated With an Epizootic Among Livestock — North Dakota, 2000

On August 28, 2000, the North Dakota Department of Health was notified by a local clinician of a patient with a cutaneous lesion suggestive of anthrax following exposure to an infected animal carcass. This report summarizes the investigation of this case, which was associated with an anthrax epizootic among livestock in North Dakota, and emphasizes the importance of increased vigilance for human cases of anthrax during and following outbreaks of anthrax among livestock.

On August 19, 2000, a 67-year-old resident of eastern North Dakota participated in the disposal of five cows that had died of anthrax. On the day of disposal, he placed chains around the heads and hooves of the animals and moved them to a burial site. He reported having worn leather gloves throughout transportation and disposal.


On August 23, he noticed a small bump on his left cheek at the angle of his jaw. On August 25, the lesion had enlarged and he sought medical attention. He denied fever, malaise, headache, pruritus, or difficulty swallowing. On examination, the lesion was indurated to approximately the size of a quarter and was surrounded by a purple colored ring. The patient was afebrile and did not appear ill. The physician reported a firm, nontender, superficial nodule with an overlying 0.5 cm black eschar. No drainage was noted and neither wound nor blood cultures was obtained. The patient was placed on ciprofloxacin 500 mg twice a day for presumed cutaneous anthrax.


On follow-up examination on August 28, the eschar had enlarged to 1 cm. Following consultation with the North Dakota Department of Health and based on clinical suspicion of anthrax, the patient continued the course of ciprofloxacin for a total of 14 days. The lesion slowly improved over several weeks. Paired serum specimens were obtained on September 22 and October 5, 2000, and were tested at CDC; both had positive antibody titers by ELISA of 200 to protective antigen, confirming infection with Bacillus anthracis.

This case was associated with an anthrax epizootic in North Dakota, during which 32 farms were guarantined for anthrax in 2000*, compared with an average of two farms per year during the preceding 40 years (Figure 1). The initial cases were detected in May 2000, when four animals were found dead on a farm; the deaths were later confirmed to be associated with anthrax. During the epizootic, which extended from July 6 through September 24, 2000, 157 animals died on 31 farms on which 62 persons were involved with animal care, vaccination, specimen processing, or carcass disposal. No other cases of symptomatic anthrax were identified in humans in North Dakota.

^{*}A quarantined farm is one on which at least one case of culture-confirmed anthrax has occurred among livestock.

Human Anthrax — Continued







Reported by: L Shireley, MPH, T Dwelle, MD, D Streitz, North Dakota Dept of Health; L Schuler, DVM, North Dakota Dept of Agriculture. Animal and Plant Health Inspection Svc, US Dept of Agriculture. Meningitis and Special Pathogens Br, Div of Bacterial and Mycotic Diseases, National Center for Infectious Diseases; and an EIS Officer, CDC.

Editorial Note: This report presents the first case of cutaneous anthrax in the United States since 1992. In the United States, the annual incidence of human anthrax declined from approximately 200 cases in the early 1900s to no human cases since 1992. Although most cases reported in the United States have been cutaneous, 18 cases of inhalational anthrax were reported during the 20th century, most recently in 1976 (1). No cases of gastrointestinal anthrax have been reported in the United States.

Anthrax most commonly occurs in both wild and domestic mammals (e.g., cattle, sheep, goats, camels, antelopes, and other herbivores) (2). Humans develop anthrax infection following exposure to infected animals, tissue from infected animals, or by direct exposure to *B. anthracis* (3,4). Exposure to infected animal tissue can occur during postmortem examination, slaughter, or handling of infected meat or hides. Exposure also can occur during laboratory manipulation of infected blood, muscle, or other tissues. Human-to-human transmission of anthrax is rare.

Anthrax can occur in three forms: cutaneous, gastrointestinal, and inhalational (2). Most cases (95% worldwide) are cutaneous. The incubation period for cutaneous anthrax ranges from 12 hours to 12 days (2–5). Cutaneous anthrax may begin with pruritus at the affected site, typically followed by a small, painless papule that progresses to a vesicle in 1–2 days. The lesion erodes, leaving a necrotic ulcer with a characteristic black center. Secondary vesicles are sometimes observed, lymphadenopathy may occur, and local edema may be extensive. Patients may have fever, malaise, and head-ache. The most common sites of cutaneous anthrax are the hands, forearms, and head. Of the 203 cases reported in the United States since 1955 in which the site of infection was known, 64 (27%) have been in the head and neck region (2). Presumably, the mechanism of inoculation in this case was the transfer of infective spores on the patient's gloves to broken skin on his face.

Human Anthrax — Continued

Untreated, 20% of persons with cutaneous anthrax die, compared with <1% of those who receive antibiotic therapy (2,6). *B. anthracis* is sensitive *in vitro* to penicillin, tetracycline, chloramphenicol, and ciprofloxacin (7). In localized or uncomplicated cases of cutaneous anthrax, the recommended regimen is penicillin V, 500 mg taken orally every 6 hours for 5–7 days. For more severe cases of cutaneous anthrax, penicillin G, 4–6 million units every 6 hours intravenously for 7–10 days is recommended. Doxycycline, 100 mg twice a day for localized cases or intravenously for serious cases, also can be used (7–9).

Veterinarians and agricultural workers should minimize direct contact with animals suspected to have died of anthrax. For confirmation by smear or culture, the carcass should not be opened, and a postmortem blood sample should be obtained aseptically by a veterinarian from an accessible peripheral vein (e.g., jugular vein). Specimens also can be obtained from hemorrhagic nasal, buccal, or anal exudate or from materials contaminated with the exudate. If possible, the carcass should be burned or buried where it is found. To minimize environmental contamination, burning is the preferred disposal method. Bedding and other materials found around the carcass (e.g., contaminated soil) also should be burned or buried, and all remaining animals should be promptly removed from the affected pasture. Farms where anthrax deaths among livestock are confirmed should be quarantined and all susceptible healthy livestock on the affected and neighboring premises vaccinated with the Sterne vaccine. Where anthrax is suspected or confirmed, use of long-acting antibiotics followed by vaccination may be effective in reducing livestock deaths. However, this regimen has not been systematically evaluated.

Because this epizootic may continue in North Dakota and because anthrax cases among livestock occur each year, health-care providers should consider the possibility of anthrax when evaluating patients with characteristic skin lesions, particularly if the exposure history includes handling of animals with confirmed or suspected anthrax. Vigilance for human cases of anthrax should be heightened during anthrax epizootics. Veterinary health services should work closely with public and private health officials to ensure early detection and treatment of possible human anthrax cases resulting from exposure to animals during an epizootic. Any person who handles carcasses of animals that have died or are suspected to have died of anthrax should contact their health-care provider if they develop a skin lesion. Although veterinarians, agricultural workers, and laboratory workers might be at increased risk for *B. anthracis* infection during these epizootics, the risk is low and anthrax vaccination is not recommended (*10*).

References[†]

- 1. Brachman PS. Inhalational anthrax. Ann NY Acad Sci 1980;353:83-93.
- 2. Brachman PS, Kaufmann A. Anthrax. In: Evans AS, Brachman PS, eds. Bacterial Infections of Humans. New York, New York: Plenum Medical Book Company, 1998.
- Bell JH. On anthrax and athracaemia in wool sorters, heifers, and sheep. Br Med J 1880;2:656-61.
- 4. Davies JC. A major epidemic of anthrax in Zimbabwe. Cent Afr J Med 1982;28:291-8.
- Turnbull PCB. Guidelines for the surveillance and control of anthrax in humans and animals. Geneva, Switzerland: World Health Organization, 1998; (publication no. WHO/ EMC/ZDI/98.6).
- 6. Dixon TC, Meselson M, Guillemin J, Hanna PC. Anthrax. N Engl J Med 1999;341:815–26.

[†] All *MMWR* references are available on the Internet at <http://www.cdc.gov/mmwr>. Use the search function to find specific articles.

Human Anthrax — Continued

- 7. Lightfoot NF, Scott RJD, Turnbull PCB. Antimicrobial susceptibility of *Bacillus anthracis*. Salisbury Med Bull 1990;68:95–8.
- 8. Barnes JM. Penicillin and B. anthracis. Journal of Pathology and Bacteriology 1947;194:113-25.
- 9. Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997;278:399-411.
- Ashford DA, Rotz LD, Perkins BA. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practice (ACIP). MMWR 2000; 49(no. RR–15).

Botulism Outbreak Associated With Eating Fermented Food — Alaska, 2001

On January 18, 2001, the Alaska Division of Public Health was informed by a local physician of a possible botulism outbreak in a southwest Alaska village. This report summarizes the findings of the outbreak investigation, which linked disease to eating fermented food, and describes a new botulism prevention program in Alaska.

A case of foodborne botulism was defined as a clinically compatible illness in a village resident with laboratory confirmation of botulism or a history of eating the same food as a laboratory-confirmed case; 14 persons in the village had eaten fermented beaver tail and paw on January 17. Approximately 20 hours later, three of the 14 had symptoms suggestive of botulism, including dry mouth, blurry vision, and general weakness. Two patients developed respiratory failure and required intubation and mechanical ventilation. One of the two intubated patients suffered cardiac arrest and underwent successful cardiopulmonary resuscitation. Approximately 6 hours after the onset of symptoms, the three patients received types A/B and E botulism antitoxin. They subsequently were evacuated to an intensive care unit (ICU) in Anchorage. Two patients recovered without further complication. The third required tracheostomy tube placement and mechanical ventilation for 1 month; this patient had been hospitalized with botulism in 1997. Of the other 11 exposed persons, four reported minor symptoms compatible with botulism, including dry mouth and nausea, and were admitted to a hospital for overnight observation. One was hospitalized for 10 days with persistent ileus. The remaining seven exposed persons were held for observation for 48 hours.

Clinical specimens from the 14 exposed persons were tested for botulinum toxin at CDC. Type E toxin was detected in serum specimens from two of the ICU patients and in stool from the third. Although they displayed minor symptoms, the other 11 persons had no toxin found in specimens and were not considered laboratory-confirmed cases. Type E toxin also was detected in three beaver paws tested from the implicated meal.

Beaver is hunted in southwest Alaska, and certain parts often are fermented and eaten later. In this outbreak, the tail and paws had been wrapped in a paper rice sack and stored for up to 3 months in the entry of a patient's house. Some of the beaver tail and paw had been added to the sack as recently as 1 week before it was eaten.

Reported by: A Horn, K Stamper, D Dahlberg, J McCabe, MD, Bristol Bay Area Health Corporation, Dillingham; M Beller, MD, JP Middaugh, MD, State Epidemiologist, Alaska Dept of Health and Social Svcs. Arctic Investigations Program; Foodborne and Diarrheal Diseases Br, Div of Bacterial and Mycotic Diseases, National Center for Infectious Diseases; and EIS officers, CDC.


Editorial Note: This report illustrates how the use of nontraditional fermentation methods is associated with foodborne botulism in Alaska. Botulism results from eating preformed

Botulism Outbreak — Continued

toxin produced by *Clostridium botulinum*. Botulism begins with cranial nerve paralysis, including diplopia, dilated and fixed pupils, dysarthria, dysphagia, and dry throat. Botulism intoxication can result in death, which most often is caused by respiratory failure. The latent period is typically 12–36 hours but can range from 6 hours to 10 days (1). *C. botulinum* and closely related organisms produce toxins designated as types A, B, C, D, E, F, and G. Human botulism is most commonly caused by types A, B, and E. Type E is associated with foods of marine or freshwater origin. Alaska's foodborne botulism rates exceed those in any other state and are among the highest in the world (1). During 1950–2000, Alaska recorded 226 cases of foodborne botulism from 114 outbreaks. All patients were Alaska Natives, and all cases with known causes were associated with eating fermented foods (1,2). Approximately 27% of U.S. foodborne botulism cases occur in Alaska.

In traditional fermentation, food is kept in a grass-lined hole in the ground or a wooden barrel sunken into the ground or is placed in a shady area above ground for several weeks to months. Since the 1970s, however, plastic or glass containers have been used and fermentation has been done above ground or indoors. The anaerobic condition of sealed containers and warmer temperatures make fermentation more rapid and production of botulism toxin more likely (3-5). These nontraditional methods have been associated with increased botulism rates in Alaska during 1970–1989 (Figure 1) (4,5). Although a plastic container was not used in this outbreak, the beaver tail and paw were fermented in a closed rice sack and stored in a warm area.

FIGURE 1. Incidence* of foodborne botulism among Alaska Natives, by 5-year intervals — Alaska, 1950–1999



5-Year Interval

*Per 100,000 population.

Botulism Outbreak — Continued

Early diagnosis and antitoxin treatment have contributed to the decline of the casefatality rate from approximately 31% during 1950–1959 to no deaths in Alaska since 1994 (1). However, Alaska continues to have high foodborne botulism rates because fermented foods are part of Alaska Native culture. In a 1999 survey, 107 (77%) of 140 Alaska Natives reported having eaten fermented foods at least once in their lifetime (3).

In 1998, the Bristol Bay Area Health Corporation, a health-care delivery organization operated by Alaska Natives in southwest Alaska, collaborated with CDC's Arctic Investigations Program to design a community-based botulism prevention strategy, including an education video entitled, "A Helping Hand: Keeping Your Family Safe From Botulism." It features Alaska Native elders and botulism survivors discussing the risks of eating improperly fermented foods and recommends returning to traditional methods. The video also suggests boiling fermented foods for 10 minutes to destroy botulinum toxin. Both an English and an Alaska Native language version of the video were produced and distributed to all village clinics and schools in the Bristol Bay region. Information on botulism prevention also is available at http://www.cdc.gov/phtn/botulism/default/ default.htm.

References

- Beller M. Botulism in Alaska: a guide for physicians and health-care providers—1998 update. Anchorage, Alaska: Alaska Department of Health and Social Services, 1998. Available at http://www.epi.hss.state.ak.us/pubs/botulism/bot_01.htm. Accessed August 2001.
- Wainwright RB, Heyward WL, Middaugh JP, Hatheway CL, Harpster AP, Bender TR. Foodborne botulism in Alaska, 1947–1985: epidemiology and clinical findings. J Inf Dis 1988; 157:1158–62.
- 3. Chiou L, Hennessy T, Horn A, Carter G, Butler J. A survey of knowledge, attitudes, and practices related to fermented foods known to cause botulism among Alaska Natives of southwest Alaska. [Abstract]. Presented at the 2nd International Conference on Emerging Infectious Diseases, Atlanta, Georgia, July 2000.
- 4. Eisenberg MS, Bender TR. Plastic bags and botulism: a new twist to an old hazard of the north. Alaska Med; July 1976:47–9.
- Shaffer N, Wainwright RB, Middaugh JP. Botulism among Alaska Natives: the role of changing food preparation and consumption practices. West J Med 1990;153:390–3.

Self-Reported Asthma Prevalence Among Adults — United States, 2000

Asthma is a chronic inflammatory disorder of the airways characterized by episodes of wheezing, shortness of breath, chest tightness, and cough and is among the most common chronic diseases in the United States, affecting approximately 10.2 million adults during 1996 (1). Direct and indirect costs associated with asthma during 1998 were an estimated \$12.7 billion (2). Despite the prevalence and associated costs of asthma, state-specific data have not been available (3,4). This report summarizes state asthma prevalence data collected from the 2000 Behavioral Risk Factor Surveillance System (BRFSS) survey, which indicated that approximately 7.2% of adults residing in the United States reported having asthma. This is the first state-specific asthma prevalence will allow state health departments to monitor trends in asthma prevalence and to provide data to direct asthma management.

Self-Reported Asthma — Continued

BRFSS is a state-based, random-digit-dialed survey of the noninstitutionalized U.S. population aged \geq 18 years; the survey collects information about modifiable risk factors for chronic diseases and other leading causes of death (5). CDC and state and territorial departments of health use the system to monitor trends that affect public health decisions. During 1999, the first optional two-item module on asthma was added to the BRFSS questionnaire. During 2000, the asthma questions were used in the 50 states, Puerto Rico, and the District of Columbia. Two asthma case definitions were constructed. Lifetime asthma was defined as answering "yes" to "Have you ever been told by a doctor that you have asthma?" Current asthma was defined as answering "yes" and "Do you still have asthma?" Weighted prevalence estimates and 95% confidence intervals were calculated using SUDAAN to account for the complex survey design (6).

The median response rate was 51.3% (from 33.4% in New Jersey to 75.5% in Minnesota). On the basis of answers from 182,293 respondents, the overall prevalence of lifetime asthma was 10.5%. The median rate of lifetime asthma from the 52 reporting areas was also 10.5% (from 8.0% in Louisiana to 15.9% in Puerto Rico) (Table 1). During 2000, an estimated 14.6 million adults had current asthma; the overall prevalence of current asthma was 7.2%. The median rate of current asthma from the 52 reporting areas was 7.3% (from 5.0% in Louisiana to 8.9% in Maine) (Table 1). Current asthma was higher among blacks (8.5%) than whites (7.1%) and persons of other race/ethnicity (5.6%). The prevalence of current asthma decreased with increasing family income (from 9.8% among persons with family incomes of <\$15,000 to 5.9% among persons with family incomes of >\$75,000). Women had higher rates of current asthma than men both overall (9.1% versus 5.1%) and in each reporting area (Table 2).

Reported by the following BRFSS coordinators: S Reese, Alabama; P Owen, Alaska; R Weyant, Arizona; B Woodson, Arkansas; B Davis, California; M Leff, Colorado; M Adams, Connecticut; F Breukelman, Delaware; I Bullo, District of Columbia; S Oba, Florida; L Martin, Georgia; F Reyes-Salvail, Hawaii; J Aydelotte, Idaho; B Steiner, Illinois; L Stemnock, Indiana; J Davila, Iowa; C Hunt, Kansas; T Sparks, Kentucky; B Bates, Louisiana; D Maines, Maine; A Weinstein, Maryland; D Brook, Massachusetts; H McGee, Michigan; N Salem, Minnesota; D Johnson, Mississippi; J Jackson, Missouri; P Feigley, Montana; L Andelt, Nebraska; E DeJan, Nevada; J Taylor, New Hampshire; G Boeselager, New Jersey; W Honey, New Mexico; C Baker, New York; Z Gizlice, North Carolina; L Shireley, North Dakota; P Coss, Ohio; K Baker, Oklahoma; K Pickle, Oregon; L Mann, Pennsylvania; Y Cintron, Puerto Rico; J Hesser, Rhode Island; M Wu, South Carolina; M Gildemaster, South Dakota; D Ridings, Tennessee; K Condon, Texas; K Marti, Utah; C Roe, Vermont; J Hicks, Virginia; K Wynkoop-Simmons, Washington; F King, West Virginia; K Pearson, Wisconsin; M Futa, Wyoming. Air Pollution and Respiratory Health Br, Div of Environmental Hazards and Health Effects, National Center for Environmental Health; and an EIS Officer, CDC.

Editorial Note: This report provides the first estimates of self-reported asthma in U.S. adults collected and reported at the state level. Previous state estimates were calculated using National Health Interview Survey regional data and demographic data from the states. In 1998, national prevalence of current asthma among adults and children was 6.4% (from 5.8% in Florida, Oklahoma, and West Virginia to 7.2% in Nevada) (7). BRFSS data indicate no consistent regional pattern and some variability among the states. Possible reasons for this variability include demographic, socioeconomic (e.g., income and education levels) and environmental factors (e.g., outdoor air pollution and climate), physician diagnostic procedures, or response rates. Asthma rates consistently were

Self-Reported Asthma — Continued

		ne Asthma Preva	lence Cu	rrent Asthma P	Asthma Prevalence				
Area	No.		% Cl [§]) No		(95% CI)				
Alabama	2,238	9.1 (7.8	-10.5) 2,23	33 6.1	(5.0- 7.2)				
Alaska	2,079		-13.6) 2,07		(5.3-8.5)				
Arizona	2,677		-13.5) 2,67		(6.3-10.9)				
Arkansas	3,003		- 9.1) 2,99		(5.6-7.6)				
California	3,905		-12.7) 3,89		(6.4-8.2)				
Colorado	3,055		-10.9) 3,05		(5.4-7.7)				
Connecticut	3,909		–11.9) 3,89		(6.9-8.8)				
Delaware	2,756		–12.0) 2,74		(5.8-8.4)				
District of Columb			-12.7) 1,70		(6.5-9.4)				
Florida	5,195	9.1 (8.2	-10.0) 5,18	31 5.7	(5.0 - 6.4)				
Georgia	4,104	9.6 (8.4	-10.8) 4,08	6.2	(5.3-7.1)				
Hawaii	6,015	11.4 (10.3	-12.5) 6,00	7.3	(6.4-8.3)				
Idaho	4,976	10.8 (9.8	–11.8) 4,96		(6.8- 8.5)				
Illinois [¶]	1,856		-12.2) 1,85		(6.4-9.4)				
Indiana	2,919	11.2 (9.8	-12.6) 2,91		(7.0-9.2)				
lowa	3,608	8.5 (7.4	- 9.6) 3,59		(5.4 - 7.2)				
Kansas	4,234		-12.0) 4,22		(6.9-8.7)				
Kentucky	6,402		-11.8) 6,39		(6.9-8.7)				
Louisiana	5,006	8.0 (7.2	- 8.9) 4,99	94 5.0	(4.4– 5.7)				
Maine	4,596	12.5 (10.8	-14.1) 4,58	8.9	(7.6–10.3)				
Maryland	4,587	10.6 (9.4	–11.7) 4,58		(6.4 - 8.2)				
Massachusetts	8,139	11.9 (11.0	-12.8) 8,12	2 8.5	(7.8-9.2)				
Michigan	2,602	10.3 (8.9	-11.7) 2,59		(6.2-8.5)				
Minnesota	2,848	9.5 (8.2	-10.8) 2,84	2 7.2	(6.1-8.3)				
Mississippi	2,177	9.9 (8.3	–11.4) 2,17	6.8	(5.4-8.1)				
Missouri	4,384	10.6 (9.3	–11.9) 4,37		(6.2-8.3)				
Montana	3,014		-13.0) 3,00		(7.0-9.6)				
Nebraska	3,092		- 9.9) 3,09		(5.5-7.6)				
Nevada	2,100	13.4 (11.3	-15.6) 2,09	8.3	(6.6-9.9)				
New Hampshire	1,955	12.0 (10.3	-13.7) 1,95	52 8.3	(7.0- 9.7)				
New Jersey	3,776	8.7 (7.6	- 9.7) 3,77	6.2	(5.3– 7.0)				
New Mexico	3,247	10.0 (8.9	–11.2) 3,23	6.9	(6.0- 7.9)				
New York	3,355	10.7 (9.5	–11.9) 3,34	7.7	(6.6- 8.7)				
North Carolina	3,011	10.1 (8.9	-11.4) 3,00)8 7.1	(6.1-8.2)				
North Dakota	1,913	9.2 (7.7	–10.7) 1,91	2 7.4	(6.1- 8.8)				
Ohio	3,253	10.9 (9.4	–12.4) 3,24	8.6	(7.2–10.0)				
Oklahoma	3,686	9.2 (8.1	-10.2) 3,68	6.3	(5.5–7.2)				
Oregon	3,741		–13.2) 3,73	80 8.5	(7.6– 9.5)				
Pennsylvania	3,534	9.3 (8.2	–10.4) 3,52	.6 6.6	(5.7– 7.4)				
Puerto Rico	4,205	15.9 (14.4	–17.3) 4,20)4 7.5	(6.6– 8.5)				
Rhode Island	3,537	11.7 (10.5	–13.0) 3,52	23 8.5	(7.5– 9.5)				
South Carolina	3,312	10.4 (9.2	–11.6) 3,30	6.8	(5.8– 7.7)				
South Dakota	4,995	8.0 (7.2	- 9.0) 4,98	34 5.6	(4.9– 6.3)				
Tennessee	3,034	10.4 (9.2	–11.7) 3,02		(6.3– 8.3)				
Texas	5,015	10.5 (9.6	–11.4) 5,00	6.5	(5.8– 7.3)				
Utah	2,888	10.3 (8.9	–11.8) 2,88		(6.3- 9.0)				
Vermont	3,626	9.7 (8.7	–10.8) 3,62	21 7.2	(6.2- 8.1)				
Virginia	1,991	10.5 (8.9	–12.2) 1,98		(5.7– 8.5)				
Washington	3,578		–13.1) 3,57		(7.2-9.2)				
West Virginia	2,351		–13.2) 2,34		(7.3-9.7)				
Wisconsin	2,716		–11.9) 2,71		(6.6-8.9)				
Wyoming	2,385	11.8 (10.4	–13.2) 2,37	8.6	(7.4– 9.9)				
Total	182,293		–10.7) 181,91		(7.0-7.4)				
* Answering "ves"	to "House								

TABLE 1. Estimated lifetime* and current⁺ asthma prevalence — Behavioral Risk Factor Surveillance System (BRFSS), United States, Puerto Rico, and the District of Columbia, 2000

* Answering "yes" to "Have you ever been told by a doctor that you have asthma?"
* Answering "yes" to "Have you ever been told by a doctor that you have asthma?" and "Do you still have asthma?"
* Confidence interval.

[¶] Estimates are inexact because Illinois deviated from standard BRFSS sampling methodology.

Self-Reported Asthma — Continued

		Men			Women	
Area	No.	(%)	(95% Cl ⁺)	No.	(%)	(95% CI)
Alabama	833	4.9	(3.2- 6.5)	1,400	7.2	(5.8– 8.7)
Alaska	985	4.3	(2.6- 5.9)	1,091	9.7	(7.0–12.5)
Arizona	1,084	7.0	(3.3–10.7)	1,586	10.0	(7.2–12.8)
Arkansas	1,153	4.4	(3.1– 5.7)	1,844	8.6	(7.0–10.1)
California	1,642	5.6	(4.4– 6.8)	2,256	9.0	(7.6–10.4)
Colorado	1,292	5.3	(3.8- 6.8)	1,759	7.8	(6.0- 9.5)
Connecticut	1,518	5.9	(4.5- 7.2)	2,380	9.6	(8.3–10.9)
Delaware	1,128	5.9	(3.9– 7.8)	1,617	8.3	(6.6–10.0)
District of Columbi	a 668	5.8	(3.7– 7.8)	1,037	9.8	(7.7–11.9)
Florida	2,089	4.1	(3.2- 5.0)	3,092	7.2	(6.1- 8.3)
Georgia	1,566	4.8	(3.5– 6.2)	2,523	7.5	(6.2- 8.7)
Hawaii	2,675	5.4	(4.2- 6.7)	3,332	9.3	(7.9–10.6)
Idaho	2,112	6.2	(5.0- 7.4)	2,853	9.1	(7.9–10.3)
Illinois⁵	785	4.9	(3.1- 6.7)	1,069	10.8	(8.5–13.1)
Indiana	1,206	5.8	(4.3– 7.4)	1,707	10.2	(8.5–11.8)
lowa	1,419	5.7	(4.4– 7.0)	2,180	6.9	(5.7- 8.2)
Kansas	1,641	6.0	(4.7– 7.4)	2,586	9.5	(8.3–10.8)
Kentucky	2,542	5.5	(4.4-6.6)	3,849	9.8	(8.5–11.2)
Louisiana	1,874	3.6	(2.7- 4.6)	3,120	6.3	(5.3-7.3)
Maine	1,883	6.9	(5.0- 8.8)	2,706	10.8	(8.9–12.8)
Maryland	1,778	4.3	(3.2- 5.4)	2,802	10.0	(8.6–11.5)
Massachusetts	3,212	6.8	(5.7–7.8)	4,910	10.1	(9.0–11.1)
Michigan	1,119	4.9	(3.3- 6.5)	1,474	9.6	(7.8–11.3)
Minnesota	1,253	5.0	(3.7- 6.4)	1,589	9.2	(7.6–10.9)
Mississippi	822	5.9	(3.7-8.1)	1,350	7.6	(6.0- 9.2)
Missouri	1,693	5.9	(4.5-7.4)	2,683	8.4	(6.9-9.9)
Montana	1,286	7.2	(5.2- 9.1)	1,721	9.4	(7.5–11.2)
Nebraska	1,243	4.2	(2.9-5.5)	1,848	8.8	(7.1–10.4)
Nevada	1,039	6.6	(4.4– 8.8)	1,054	9.9	(7.5–12.4)
New Hampshire	788	6.7	(4.6-8.7)	1,164	9.9	(8.0–11.8)
New Jersey	1,472	4.5	(3.3- 5.7)	2,300	7.7	(6.5- 8.9)
New Mexico	1,468	5.5	(4.3- 6.8)	1,770	8.2	(6.8- 9.6)
New York	1,332	4.9	(3.6- 6.1)	2,015	10.2	(8.6–11.8)
North Carolina	1,143	4.7	(3.4- 5.9)	1,865	9.4	(7.8–11.0)
North Dakota	813	6.1	(4.3– 7.8)	1,099	8.8	(6.8–10.8)
Ohio	1,272	5.8	(4.0-7.7)	1,975	11.1	(9.1–13.0)
Oklahoma	1,567	5.1	(3.9 - 6.2)	2,115	7.5	(6.3- 8.7)
Oregon	1,488	5.6	(4.4- 6.8)	2,242	11.3	(9.8–12.7)
Pennsylvania	1,421	3.6	(2.7- 4.6)	2,108	9.2	(7.8–10.5)
Puerto Rico	1,544	5.4	(4.0- 6.9)	2,660	9.4	(8.1–10.8)
Rhode Island	1,370	5.9	(4.5-7.4)	2,153	10.8	(9.3–12.2)
South Carolina	1,319	3.9	(2.7-5.1)	1,987	9.4	(8.0–10.8)
South Dakota	1,927	4.6	(3.6- 5.6)	3,057	6.5	(5.5– 7.5)
Tennessee	995	4.3	(3.0- 5.6)	2,031	10.0	(8.5–11.6)
Texas	2,011	4.8	(3.7- 5.8)	2,995	8.2	(7.1-9.3)
Utah	1,259	5.8	(4.1-7.6)	1,623	9.4	(7.4–11.3)
Vermont	1,511	6.1	(4.8-7.4)	2,110	8.1	(6.8-9.4)
Virginia	846	4.5	(2.7- 6.3)	1,137	9.5	(7.4–11.6)
Washington	1,482	5.8	(4.6-7.1)	2,088	10.5	(9.0–11.9)
West Virginia	953	6.7	(5.0- 8.4)	1,393	10.1	(8.4–11.9)
Wisconsin	1,218	5.5	(4.0-7.1)	1,492	9.8	(8.1–11.5)
Wyoming	1,003	6.5	(4.9-8.1)	1,375	10.7	(8.9–12.6)
Total	73,742	5.1	(4.9- 5.4)	108,172	9.1	(8.8- 9.4)

TABLE 2. Estimated current asthma* prevalence, by sex — Behavioral Risk Factor Surveillance System (BRFSS), United States, Puerto Rico, and the District of Columbia, 2000

* Answering "yes" to "Have you ever been told by a doctor that you have asthma?" and "Do you still have asthma?"

[†] Confidence interval.

[§] Estimates are inexact because Illinois deviated from standard BRFSS sampling methodology.

Self-Reported Asthma — Continued

higher among women than men. Higher rates among women have been described for both prevalence and other measures of asthma (e.g., hospitalization and mortality) (3) and may be associated with hormones, obesity, or other factors (8,9). It is unclear whether variability in rates reflects a true difference in prevalence, differences in reporting, or other factors.

The findings in this report are subject to at least three limitations. First, the median response rate for the survey was only 51.3%. Second, BRFSS does not measure asthma prevalence in institutionalized adults, persons aged <18 years, and residents without telephones; the percentage of households with telephones ranges from 87% (Mississippi) to 98% (Massachusetts) (6). Third, the validity of self-reported asthma status in BRFSS is unknown. BRFSS case definitions include respondents who have been told by a physician that they have asthma; either the physician's diagnosis or the subjects' recall of that diagnosis may be inaccurate. A 1998 review of asthma questionnaires reported a mean sensitivity of 68% (range: 48%–100%) and a mean specificity of 94% (range: 78%–100%) when self-reported asthma was compared with a clinical diagnosis of asthma (10).

The continued use of the BRFSS asthma questions will allow state health departments to monitor trends in asthma prevalence and to provide data to direct asthma management. In addition, the data will provide state-specific information on asthma prevalence by age, race/ethnicity, education level, and family income.

References*

- CDC. Vital and health statistics: current estimates from the National Health Interview Survey, 1996. Hyattsville, Maryland: US Department of Health and Human Services, CDC, 1999.
- 2. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis: assessing the economic impact. J Allergy Clin Immunol 2001;107:3–8.
- Mannino D, Homa D, Pertowski C, et al. Surveillance for asthma—United States, 1960– 1995. MMWR 1998;47(no. SS-1).
- 4. Boss LP, Kreutzer RA, Luttinger D, Leighton J, Wilcox K, Redd SC. The public health surveillance of asthma. J Asthma 2001;38:83–9.
- CDC. Tracking major health risks among Americans: the Behavioral Risk Factor Surveillance System. Atlanta, Georgia: US Department of Health and Human Services, CDC, 2000.
- CDC. Behavioral Risk Factor Surveillance System user's guide. Atlanta, Georgia: US Department of Health and Human Services, CDC, 1999.
- CDC. Forecasted state-specific estimates of self-reported asthma prevalence—United States, 1998. MMWR 1998;47:1022–5.
- Troisi RJ, Speizer FE, Willett WC, Trichopoulos D, Rosner B. Menopause, postmenopausal estrogen preparations, and the risk of adult-onset asthma: a prospective cohort study. Am J Respir Crit Care Med 1995;152:1183–8.
- 9. Camargo CA, Weiss ST, Zhang S, Willett WC, Speizer FE. Prospective study of body mass index, weight change and risk of adult-onset asthma in women. Arch Internal Med 1999;159:2582–8.
- 10. Toren K, Brisman J, Jarvholm B. Asthma and asthma-like symptoms in adults assessed by questionnaires: a literature review. Chest 1993;104:600–8.

^{*}All *MMWR* references are available on the Internet at <http://www.cdc.gov/mmwr>. Use the search function to find specific articles.

Notice to Readers

Draft of Guidelines for the Prevention of Opportunistic Infections (OIs) in Persons Infected with Human Immunodeficiency Virus

The 2001 Guidelines for the Prevention of Opportunistic Infections (OIs) in Persons Infected with Human Immunodeficiency Virus are now available in draft form on the AIDS Treatment and Information Service website (http://www.hivatis.org). These guidelines, originally published in 1995 and revised in 1997 and 1999, address prevention of 19 HIV-associated OIs, or groups of OIs, with regard to preventing exposure to the infectious agent, preventing disease by chemoprophylaxis or vaccination (primary prophylaxis), and preventing disease recurrence in persons already treated for an OI (secondary prophylaxis). The guidelines include recommendations for adults and children, with specific information on care of pregnant women. As in earlier editions of the guidelines, recommendations are rated using a system that indicates the strength of each recommendation and quality of evidence supporting it.

The primary changes in the 2001 guidelines pertain to discontinuing chemoprophylaxis in patients whose CD4+ lymphocyte counts have increased in response to highly active antiretroviral therapy. Since the 1999 guidelines, new or strengthened recommendations are offered concerning discontinuation of primary prophylaxis against *Pneumocystis carinii* pneumonia (PCP), toxoplasmic encephalitis (TE), and disseminated *Mycobacterium avium* complex (MAC) disease; and for discontinuation of secondary prophylaxis against PCP, cytomegalovirus retinitis, disseminated MAC, TE, and cryptococcal meningitis. Other changes include new information on drug interactions and revised recommendations for vaccinating HIV-exposed/infected children.

The 2001 guidelines were developed by representatives of U.S. government agencies, professional organizations, academic institutions, and patient advocacy groups after reviewing published manuscripts, abstracts, and material presented at scientific meetings.

Comments on the guidelines may be addressed to Henry Masur, M.D., <hmasur@nih.gov> and will be accepted until September 1, 2001. After this date, the document will be revised and finalized. The guidelines are expected to be updated periodically as new information becomes available.

Notice to Readers

Epidemiology in Action

CDC and Emory University's Rollins School of Public Health will co-sponsor a course, "Epidemiology in Action" from November 5–16, 2001, at CDC and Emory University campuses. The course is designed for state and local public health professionals.

The course emphasizes the practical application of epidemiology to public health problems and will consist of lectures, workshops, classroom exercises (including actual epidemiologic problems), and roundtable discussions. Topics include descriptive epidemiology and biostatistics, analytic epidemiology, epidemic investigations, public health

Notices to Readers — Continued

surveillance, surveys and sampling, Epi Info 2000 (Windows[®] version) training, and discussions of selected prevalent diseases. There is a tuition charge. Deadline for application is September 15. Additional information and applications are available from Emory University, International Health Dept.(PIA), 1518 Clifton Road, N.E., Room 746, Atlanta, GA 30322; telephone (404) 727-3485; fax (404) 727-4590; or from <http:// www.sph.emory.edu/EPICOURSES>*; or e-mail pvaleri@sph.emory.edu.

^{*}References to sites of non-CDC organizations on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites.

690




FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals ending August 11, 2001, with historical data

* Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

		Cum. 2001		Cum. 2001
Anthrax		-	Poliomyelitis, paralytic	-
Brucellosis*		46	Psittacosis*	9
Cholera		4	Q fever*	15
Cyclosporiasis	*	81	Rabies, human	1
Diphtheria		1	Rocky Mountain spotted fever (RMSF)	269
Ehrlichiosis:	human granulocytic (HGE)*	112	Rubella, congenital syndrome	-
	human monocytic (HME)*	40	Streptococcal disease, invasive, group A	2,456
Encephalitis:	California serogroup viral*	10	Streptococcal toxic-shock syndrome*	42
•	eastern equine*	2	Syphilis, congenital §	84
	St. Louis [*]	-	Tetanus	15
	western equine*	-	Toxic-shock syndrome	79
Hansen diseas	se (leprosy)*	46	Trichinosis	14
Hantavirus pu	Imonary syndrome*	4	Tularemia*	58
Hemolytic ure	mic syndrome, postdiarrheal*	67	Typhoid fever	151
HIV infection,	pediatric*1	98	Yellow fever	-
Plague	•	2		

TABLE I. Summary of provisional cases of selected notifiable diseases, United States, cumulative, week ending August 11, 2001 (32nd Week)

-: No reported cases. *Not notifiable in all states.

¹ Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention (NCHSTP). Last update June 26, 2001. [§] Updated from reports to the Division of STD Prevention, NCHSTP.

		DS	Chlan	nydia⁺	Cruntos	poridiosis	NE		<i>coli</i> O157:H7	/* LIS
Demonstrum Amore	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.
Reporting Area	2001 ^s 19,145	2000 23,248	2001 407,630	2000 420,126	2001 1,169	2000 1,141	2001 1,264	2000 2,366	2001 977	2,092
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	746 20 17 10 411 53 235	1,317 20 21 17 837 54 368	13,499 668 797 364 6,253 1,659 3,758	14,220 870 641 329 6,020 1,560 4,800	54 6 3 20 18 3 4	63 10 8 14 20 2 9	141 17 22 10 71 6 15	228 14 19 24 108 11 52	92 15 17 5 28 6 21	237 18 22 24 109 11 53
MID. ATLANTIC Jpstate N.Y. N.Y. City N.J. Pa.	3,974 322 1,996 960 696	5,374 539 2,958 1,065 812	46,085 8,164 17,748 6,272 13,901	39,865 840 16,528 7,340 15,157	140 56 57 4 23	190 51 98 7 34	95 73 4 18 N	254 151 17 86 N	102 66 7 29	183 38 10 81 54
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	1,408 237 165 665 261 80	2,253 344 214 1,289 297 109	57,843 8,627 8,643 15,799 18,016 6,758	72,293 18,734 7,873 20,506 15,256 9,924	370 87 38 1 87 157	292 32 20 46 41 153	292 82 45 64 36 65	546 84 68 123 65 206	196 64 25 41 39 27	437 110 60 94 54 119
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	454 85 47 218 1 18 39 46	568 101 60 277 2 4 38 86	21,056 4,025 1,858 8,083 569 957 2,018 3,546	23,675 4,846 3,243 8,064 553 1,102 2,266 3,601	151 77 37 12 6 6 13	116 21 38 16 7 9 21 4	213 85 37 29 9 13 26 14	337 82 87 76 8 23 44 17	171 69 28 42 17 8 - 7	347 104 85 64 15 33 35 11
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	6,167 116 751 465 501 49 402 350 757 2,776	6,200 111 705 448 395 37 371 486 704 2,943	77,947 1,755 7,126 1,764 11,466 1,429 12,446 7,062 14,507 20,392	78,351 1,790 8,273 1,913 9,780 1,290 13,482 5,117 16,811 19,895	183 28 9 15 1 19 - 63 46	172 4 8 6 5 3 16 - 76 54	110 1 9 - 31 4 27 3 15 20	178 1 - 38 10 37 11 29 38	72 3 U 20 3 17 9 12 7	181 - U 38 7 45 12 35 43
E.S. CENTRAL Ky. Tenn. Ala. Miss.	977 201 293 224 259	1,097 127 438 301 231	29,371 5,404 8,827 8,208 6,932	30,027 4,851 8,731 8,955 7,490	27 3 6 10 8	32 5 7 10 10	63 30 21 10 2	77 23 31 5 18	59 33 23 - 3	70 24 35 4 7
W.S. CENTRAL Ark. _a. Okla. Tex.	2,058 104 472 107 1,375	2,383 111 366 185 1,721	62,436 4,358 10,084 6,606 41,388	63,704 4,028 11,434 5,008 43,234	21 5 7 7 2	63 5 10 4 44	39 4 2 16 17	172 37 13 9 113	57 - 24 18 15	214 30 33 9 142
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	714 12 15 140 56 295 63 132	836 9 16 7 200 88 244 86 186	23,646 1,015 956 482 4,750 3,621 8,916 996 2,910	24,556 944 1,135 478 7,372 2,983 7,827 1,440 2,377	76 6 8 1 23 12 4 19 3	51 835 1545 83	141 8 18 7 56 8 17 19 8	229 24 29 11 90 10 34 26 5	83 - 1 44 8 9 20 1	171 21 62 9 26 39 7
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	2,647 290 112 2,204 13 28	3,220 291 107 2,727 12 83	75,747 8,313 2,599 60,927 1,673 2,235	73,435 7,912 4,238 57,647 1,483 2,155	147 N 15 129 3	162 U 10 152	170 52 23 83 3 9	345 116 58 140 22 9	145 31 20 91 - 3	252 126 62 55 1 8
Guam P.R. V.I. Amer. Samoa C.N.M.I.	9 580 2 -	13 707 24	1,638 53 U 81	310 U U U	- - - U	- - - U	N 1 - U	N 5 U U		U U U U

TABLE II. Provisional cases of selected notifiable diseases, United States,
weeks ending August 11, 2001, and August 12, 2000 (32nd Week)

N: Not notifiable. U: Unavailable. -: No reported cases. C.N.M.I.: Commonwealth of Northern Mariana Islands. * Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS). * Chlamydia refers to genital infections caused by *C. trachomatis*. Totals reported to the Division of STD Prevention, NCHSTP. * Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention. Last update June 26, 2001.

	Gono	rrhea	Hepatit Non-A, N	isC;	Legione		Listeriosis	Ly	me ease
Reporting Area	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2001	Cum. 2000
UNITED STATES	186,983	210,795	2,208	2,054	534	549	258	5,006	9,021
NEW ENGLAND Maine N.H.	3,735 79 103	4,030 51 65	14 - -	18 2 -	28 3 7	28 2 2	31 2	1,364 82	2,457 - 36
Vt. Mass. R.I. Conn.	47 1,909 422 1,175	38 1,629 380 1,867	6 8 - -	4 8 4 -	4 6 2 6	3 13 3 5	2 15 1 11	4 207 197 874	15 879 211 1,316
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	22,906 4,923 7,453 3,752 6,778	22,650 4,035 7,039 4,499 7,077	939 37 869 33	431 23 379 29	93 33 6 5 49	144 38 21 13 72	38 16 7 7 8	2,611 1,484 1 247 879	4,960 1,673 152 1,998 1,137
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	31,156 5,103 3,610 9,775 10,390 2,278	42,503 11,191 3,661 12,747 10,681 4,223	114 7 1 11 95	166 7 17 142 -	135 72 14 - 30 19	144 55 24 21 22 22	32 11 4 1 14 2	259 68 8 - 1 182	601 40 16 30 19 496
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nabe	9,003 1,325 428 4,855 18 144 697	10,422 1,937 684 5,112 42 176	449 3 - 439 - - 3	385 5 1 369 - 3	37 9 6 12 1 3 5	39 3 20 - 2 2	7 - 4 - 1	168 126 21 14 - - 3	135 69 14 36 - - 2
Nebr. Kans.	687 1,546	882 1,589	3 4	3 7	5	2 4	2	3	14
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga.	48,228 996 3,938 1,558 6,637 381 10,324 4,979 7,830	54,799 1,023 5,580 1,460 6,072 393 10,936 4,888 10,630	68 - - 9 11 5	63 2 8 2 3 12 13 1 2	113 3 24 7 17 N 5 4 6	91 5 30 - 14 N 9 3 6	42 5 8 4 2 3 7	491 31 310 7 89 9 24 2 2	716 147 414 2 91 21 29 3
Fla.	11,585	13,817	32	20	47	24	13	19	9
E.S. CENTRAL Ky. Tenn. Ala. Miss.	18,899 2,120 5,891 6,342 4,546	21,690 2,117 6,884 7,164 5,525	141 5 44 2 90	299 24 62 7 206	38 8 19 9 2	20 11 6 2 1	11 4 3 4	23 13 6 4	30 6 19 3 2
W.S. CENTRAL Ark. La. Okla. Tex.	30,453 2,692 7,058 3,041 17,662	33,294 2,240 8,223 2,153 20,678	162 3 75 3 81	522 5 282 5 230	5 - 2 3 -	20 - 7 2 11	6 1 - 2 3	7 - 1 - 6	53 5 4 44
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah	6,252 53 39 1,951 592 2,449 88	6,405 28 54 1,951 638 2,668 148	234 1 190 14 11 9 2	46 4 3 2 8 11 13	39 - 2 4 11 2 11 6	24 1 - 7 1 6 5	24 - 1 4 6 6 1	8 - 3 1 - -	5 - 1 2 - - - -
Nev. PACIFIC Wash. Oreg. Calif. Alaska Hawaii	1,043 16,351 1,855 388 13,513 232 363	882 15,002 1,370 563 12,588 191 290	6 87 16 9 62 -	5 124 19 21 82 2	3 46 6 N 36 - 4	39 14 N 25	5 67 5 1 58 - 3	1 75 4 5 64 2 N	2 64 3 55 55 1 N
Guam P.R. V.I. Amor Samaa	382 6	29 323 - U	- 1 - U	2 1 - U	- 2 - U	- 1 - U	- - -	N U	N U
Amer. Samoa C.N.M.I.	U 7	U	-	Ŭ	-	U	-	-	U

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States,
weeks ending August 11, 2001, and August 12, 2000 (32nd Week)

N: Not notifiable. U: Unavailable. -: No reported cases.

						Salmon	ellosis*	
	-	laria		s, Animal		TSS		ilis
Reporting Area	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000
UNITED STATES	627	811	3,704	4,198	18,752	21,320	14,806	18,678
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	35 3 2 11 3 16	43 4 1 2 17 5 14	378 42 7 38 145 34 112	462 87 40 149 27 151	1,365 122 124 43 802 66 208	1,319 89 84 72 780 65 229	1,118 102 115 45 460 101 295	1,364 66 84 73 775 93 273
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	134 38 57 21 18	185 40 96 26 23	690 458 16 104 112	759 469 6 101 183	2,367 689 619 501 558	2,921 675 749 709 788	2,331 622 761 527 421	3,024 769 758 579 918
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	64 18 13 1 19 13	94 13 5 49 19 8	64 20 1 9 28 6	81 19 14 37 11	2,679 828 301 664 468 418	2,888 658 344 934 538 414	2,101 630 274 429 525 243	1,884 720 362 1 578 223
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	24 6 4 8 - 2 4	37 13 9 2 - 6 6	206 23 45 20 24 25 4 65	377 56 54 31 89 70 1 76	1,210 382 188 316 16 80 89 139	1,398 315 201 440 34 57 126 225	1,243 383 185 446 49 63 - 117	1,554 426 208 516 55 63 95 191
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	178 1 74 11 36 1 9 5 8 33	177 3 66 12 35 2 13 1 4 41	1,345 25 178 265 83 360 78 223 133	1,430 27 263 370 77 363 86 157 87	4,632 53 464 848 73 627 433 708 1,378	4,030 65 454 35 553 95 556 405 670 1,197	3,072 48 481 U 497 83 570 403 745 245	3,364 83 416 U 560 90 608 319 1,003 285
E.S. CENTRAL Ky. Tenn. Ala. Miss.	19 7 8 3 1	24 8 5 10 1	130 15 80 35	118 15 66 37	1,159 195 313 354 297	1,206 226 300 322 358	892 137 365 280 110	986 166 442 311 67
W.S. CENTRAL Ark. La. Okla. Tex.	9 3 3 2 1	56 2 10 4 40	507 19 - 46 442	596 20 2 42 532	1,336 337 251 202 546	2,688 358 455 221 1,654	1,187 92 398 186 511	1,646 299 365 175 807
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	33 2 3 - 17 2 3 3 3 3	31 1 2 16 5 3 4	156 22 10 20 - 8 92 3 1	174 43 8 40 - 14 61 6 2	1,256 45 81 42 357 152 349 135 95	1,617 68 82 43 441 145 381 286 171	794 4 22 276 131 216 122 23	1,543 - 36 437 141 408 281 164
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	131 4 7 112 1 7	164 15 27 114 8	228 - 191 37 -	201 5 172 24	2,748 295 135 2,068 26 224	3,253 303 201 2,580 35 134	2,068 358 197 1,332 2 179	3,313 407 251 2,492 24 139
Guam P.R. V.I. Amer. Samoa C.N.M.I.	3 - U	- 4 - U U	64 Ū	52 U U	335 - U 8	19 380 - U U		U U U U

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States,
weeks ending August 11, 2001, and August 12, 2000 (32nd Week)

N: Not notifiable. U: Unavailable. -: No reported cases. * Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

L		Shige				philis		
-	NET Cum.	SS Cum.	Cum.	HLIS Cum.	(Primary 8 Cum.	& Secondary) Cum.	Cum.	rculosis Cum.
Reporting Area	2001	2000	2001	2000	2001	2000	2001	2000
UNITED STATES	9,265	12,888	4,355	7,202	3,326	3,720	7,112	8,488
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	143 6 4 5 98 8 22	239 6 4 3 169 19 38	116 2 2 63 18 29	228 10 7 150 20 41	29 - 1 2 17 3 6	53 1 - 36 4 11	267 7 11 2 149 21 77	253 8 12 4 151 24 54
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	842 346 226 145 125	1,744 487 736 350 171	552 76 254 157 65	1,103 175 465 293 170	293 17 155 64 57	180 7 75 43 55	1,387 188 720 314 165	1,404 186 753 330 135
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	2,172 1,462 142 248 175 145	2,604 186 921 768 509 220	990 662 25 143 141 19	782 163 117 2 462 38	554 51 103 143 240 17	775 50 238 271 181 35	744 131 63 380 135 35	826 181 82 373 134 56
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	951 286 289 167 16 92 53 48	1,389 411 301 474 4 4 64 131	735 288 237 122 14 50 -	1,164 465 234 322 12 3 55 73	46 20 1 8 - 2 15	47 7 10 25 - 2 3	272 139 18 83 3 8 21	306 97 25 115 2 13 12 42
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	1,337 5 74 32 154 7 225 165 138 537	1,672 10 109 34 284 3 102 76 149 905	402 7 45 57 7 112 74 81 19	616 11 59 U 223 3 66 61 122 71	1,210 8 141 24 70 - 283 163 193 328	1,230 5 181 22 83 2 333 137 236 231	1,459 9 125 18 149 19 206 123 235 575	1,723 8 155 173 20 225 164 372 591
E.S. CENTRAL Ky. Tenn. Ala. Miss.	866 324 60 157 325	594 200 238 34 122	382 169 69 119 25	341 50 262 26 3	377 28 208 76 65	548 58 331 76 83	441 75 160 154 52	558 69 210 182 97
W.S. CENTRAL Ark. La. Okla. Tex.	1,037 395 108 31 503	2,080 129 185 72 1,694	701 155 120 14 412	620 43 115 27 435	423 22 83 44 274	495 66 127 72 230	693 91 - 90 512	1,253 118 94 100 941
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	551 1 23 136 68 244 40 37	605 6 39 4 98 89 252 45 92	263 - - 80 41 99 35 8	418 23 3 65 53 162 51 61	141 - - 25 13 92 7 4	140 1 6 11 116 1 4	263 - 8 2 69 16 104 19 45	311 10 4 2 46 28 131 28 62
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	1,366 122 49 1,153 4 38	1,961 331 113 1,486 7 24	214 119 67 - 1 27	1,930 307 74 1,526 3 20	253 34 4 209 6	252 47 9 195 1	1,586 147 60 1,261 27 91	1,854 150 54 1,496 69 85
Guam P.R. V.I. Amer. Samoa	- 7 U	32 21 U	U U U U	U U U U	- 172 - U	2 107 Ū	54 Ū	33 92 U
C.N.M.I. N: Not notifiable.	4	U vailable.	U -: No repo	U	-	U	20	U

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending August 11, 2001, and August 12, 2000 (32nd Week)

N: Not notifiable. U: Unavailable. -: No reported cases. *Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

			T	-	12, 20		eek)	N /1	la a (Dechara	.1_)		
		<i>lenzae,</i> asive		epatitis (V	iral), By Ty B	pe	Indige	20115	Impo	les (Rubec rted*	ola) Tota	
	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.		Cum.		Cum.	Cum.	Cum.
Reporting Area	2001 [†] 858	2000 821	2001 5,621	2000 7,801	2001 3,875	2000 4,251	2001 1	<u>2001</u> 48	2001	2001 34	2001 82	2000 61
NEW ENGLAND	48	63	281	236	59	71	-	4	-	1	5	6
Maine N.H.	1	1 10	5 11	12 17	5 11	5 11	U	-	U	-	-	- 3
Vt.	2	5	8	7	3	6	-	1	-	-	1	3
Mass. R.I.	33 2	31 1	99 16	94 15	2 14	8 13	-	2	-	1	3	-
Conn.	8	15	142	91	24	28	-	1	-	-	1	-
MID. ATLANTIC Upstate N.Y.	114 47	157 62	512 164	855 141	573 84	747 82	-	2 1	-	9 4	11 5	20 9
N.Y. City N.J.	27 30	43 30	185 70	303 157	293 64	367 119	-	-	-	-	- 1	10
Pa.	30 10	30 22	93	254	132	179	-	1	-	4	5	1
E.N. CENTRAL	117	122	606	1,020	550	453	-	-	-	10	10	6
Ohio Ind.	49 35	39 19	148 56	166 42	72 29	73 30	-	-	-	3 4	3 4	2
III. Mich.	10 7	41 8	173 190	459 300	92 357	80 247	-	-	-	3	3	3 1
Wis.	16	15	39	53	-	23	-	-	-	-	-	-
W.N. CENTRAL Minn.	43 25	43 22	238 16	512 140	117 12	192 22	-	4 2	-	-	4 2	1 1
lowa	-		23	53	15	19	-	-	-	-	-	-
Mo. N. Dak.	11 4	2	60 2	223 2	59 -	103 2	Ū	2	Ū	-	2	-
S. Dak. Nebr.	2	- 3	1 28	22	1 17	- 29	-	-	-	-	-	-
Kans.	1	2	108	72	13	17	-	-	-	-	-	-
S. ATLANTIC Del.	254	193	1,299	802 10	808	718 10	-	4	-	1	5	2
Md. D.C.	60	54	171 30	105 15	91 11	81 19	-	2	-	1	3	-
Va.	18	32	82	97	96	95	-	1	-	-	1	2
W. Va. N.C.	9 32	4 19	8 92	47 100	20 131	7 154	-	-	-	-	-	-
S.C. Ga.	5 65	7 50	45 508	34 144	19 181	6 122	-	- 1	-	-	- 1	-
Fla.	65	27	363	250	259	224	-	-	-	-	-	-
E.S. CENTRAL Ky.	57 2	36 12	224 59	288 34	263 27	294 57	-	2 2	-	-	2 2	-
Tenn.	28	15	89	100	138	135	-	-	-	-	-	-
Ala. Miss.	26 1	7 2	63 13	41 113	55 43	33 69	-	-	-	-	-	-
W.S. CENTRAL	32	44	621	1,476	426	640	-	1	-	-	1	-
Ark. La.	- 3	1 13	47 48	102 52	59 29	67 91	-	-	-	-	-	-
Okla. Tex.	29	28 2	93 433	171 1,151	64 274	93 389	-	- 1	-	-	- 1	-
MOUNTAIN	115	81	526	549	354	326	-	-	-	1	1	12
Mont. Idaho	- 1	1 3	8 48	4 19	2 9	4	-	-	-	- 1	- 1	-
Wyo.	17	1	22	4	31	1	-	-	-	-	-	-
Colo. N. Mex.	26 14	17 17	50 27	132 50	73 88	53 101	-	-	-	-	-	2
Ariz. Utah	42 6	32 7	273 55	264 35	106 16	118 16	-	-	-	-	-	- 3
Nev.	9	3	43	41	29	28	-	-	-	-	-	7
PACIFIC Wash.	78 2	82 3	1,314 86	2,063 182	725 77	810 53	1	31 13	-	12 2	43 15	14 3
Oreg. Calif.	17	23 30	52 1,161	137 1,721	43 584	67 672	-	3	-	- 6	3	- 8
Alaska	32 4	6	14	11	6	9	-	12	-	-	18	1
Hawaii	23	20	1	12	15	9	1	3	-	4	7	2
Guam P.R.	- 1	1 3	62	1 178	106	9 176	U -	-	U -	-	-	- 2
V.I. Amer. Samoa	Ū	Ū	Ū	Ū	Ū	Ū	U U	Ū	U U	Ū	Ū	Ū
C.N.M.I.	-	Ŭ	-	Ŭ	23	Ŭ	-	-	-	-	-	Ŭ

by vaccination, Uni	fiable diseases preventable nding August 11, 2001, d Week)

N: Not notifiable. U: Unavailable. - : No reported cases. *For imported measles, cases include only those resulting from importation from other countries. † Of 172 cases among children aged <5 years, serotype was reported for 82, and of those, 15 were type b.

		ococcal	u /lug	Mumps	2000		Pertussis			Rubella	
Demonsting Area	Cum.	Cum.		Cum.	Cum.	0001	Cum.	Cum.		Cum.	Cum.
Reporting Area	2001 1,491	2000 1,486	2001 8	2001 134	2000 229	2001 58	2,682	2000 3,664	2001	2001 14	2000 96
NEW ENGLAND	80	87	-	-	3	1	268	951	-	-	11
Maine N.H.	1 10	7 9	U	-	-	U	- 25	14 78	U	-	-2
Vt. Mass.	4 46	2 50	-	-	- 1	1	25 202	165 649	-	-	- 8
R.I. Conn.	2 17	6 13	-	-	1	-	2 14	12 33	-	-	- 1
MID. ATLANTIC	151	170	1	13	17	2	204	333	_	4	8
Upstate N.Y. N.Y. City	44 30	47 35	1	3 7	5	2	111 33	159 49	-	1 2	1 7
N.J.	38 39	31 57	-	, - 3	3 4	-	8 52	24 101	-	1	-
Pa. E.N. CENTRAL	39 191	254	- 2	3 14	4 18	- 13	52 321	412	-	3	- 1
Ohio	65	57	-	1	7	3	192	197	-	-	-
Ind. III.	28 20	31 65	2	1 10	6	5 2	37 35	42 41	-	1 2	- 1
Mich. Wis.	44 34	73 28	-	2	4 1	3	33 24	51 81	-	-	-
W.N. CENTRAL	102	102	-	6	12	-	131	221	-	2	1
Minn. Iowa	15 21	14 21	-	2	- 5	-	31 17	123 27	-	- 1	-
Mo. N. Dak.	38 5	50 2	Ū	-	4	Ū	62	37 2	Ū	-	-
S. Dak. Nebr.	4 10	5	-	- 1	- 1	-	3 4	35	-	-	- 1
Kans.	9	6	-	3	2	-	14	24	-	1	-
S. ATLANTIC Del.	285 3	216	1	21	34	14	146	278 8	-	3	50
Md.	34	22	-	4	7	1	19	70	-	-	-
D.C. Va.	30	34	- 1	- 5	6	12	1 27	2 41	-	-	-
W. Va. N.C.	10 57	10 31	-	- 1	- 5	-	1 46	1 68	-	-	- 42
S.C. Ga.	28 35	15 37	-	1 7	10 2	-	23 7	20 25	-	2	6
Fla.	88	67	-	3	4	1	22	43	-	1	2
E.S. CENTRAL Ky.	100 18	102 21	-	3 1	4	2	70 15	81 42	-	-	5 1
Ténn. Ala.	44 29	41 29	-	-	2 2	2	31 21	23 13	-	-	1 3
Miss.	9	11	-	2	-	-	3	3	-	-	-
W.S. CENTRAL Ark.	171 12	159 11	-	8 1	24 1	8	230 8	193 29	-	-	6 1
La. Okla.	56 23	36 21	-	2	5	-	2 1	13 9	-	-	1
Tex.	23 80	91	-	5	18	8	219	142	-	-	4
MOUNTAIN Mont.	75 3	66 4	1 1	8 1	14 1	17 7	961 21	456 23	-	1	2
Idaho	7	4 6	-	-	-	-	164	44	-	-	-
Wyo. Colo. N. Mex.	6 26 11	21	-	1 1	1 -	- 5 3	1 183 73	2 246	-	- 1	- 1
N. Mex. Ariz.	11 11	6 19	-	2 1	1 3	3	73 460	75 43	-	-	- 1
Utah Nev.	7 4	7 3	-	1 1	4	2	50 9	14 9	-	-	-
PACIFIC	336	330	3	61	103	1	351	739	-	1	12 7
Wash. Oreg.	52 25	35 41	Ň	1 N	4 N	- 1	90 31	219 79	-	-	7
Calif. Alaska	248 2	241 5	-	29 1	73 8	-	199 3	394 18	-	-	5
Hawaii	9	8	3	30	18	-	28	29	-	1	-
Guam P.R.	- 3	- 7	U	-	11	U	- 2	3 5	U	-	1
V.I. Amer. Samoa	- U	, - U	U U	- U	- - U	U U	- U	- - U	U U	- U	- - U
C.N.M.I.	-	Ŭ	-	-	U	-	-	U	-	U -	U

TABLE III. (Cont'd) Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending August 11, 2001, and August 12, 2000 (32nd Week)

N: Not notifiable. U: Unavailable.

- : No reported cases.

		All Cau	uses, By	/ Age (Ye	ears)		P&I [†]	-		All Cau	ises, By	Age (Y	'ears)		P&I⁺
Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total	Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total
NEW ENGLAND Boston, Mass. Bridgeport, Conn Cambridge, Mass Fall River, Mass. Hartford, Conn. Lowell, Mass. New Bedford, Mas. New Haven, Conn Providence, R.I. Somerville, Mass. Springfield, Mass Waterbury, Conn. Worcester, Mass. MID. ATLANTIC Albany, N.Y. Allentown, Pa. Buffalo, N.Y. Camden, N.J. Elizabeth, N.J.	. 10 25 24 25 88 85. 28 28 20 20 29 57 20 57 20 57 23 96 38 37 77	320 82 9 7 222 39 17 13 21 27 0 25 55 15 15 15 41 1,484 37 19 666 18	32 2 2 1 8 4 3 5 3 0 - 2 3 8 452 12 3 17 10 4	22 4 1 2 2 4 2 1 - 1 1 3 149 5 - 8 6 2	11 5 1 - 3 - 1 U - 1 37 2 - 2 -	10 2 - 2 - 1 1 U - - 4 41 1 3 4 2	39 12 2 5 1 1 3 2 U 4 9 111 4 14 14 2 1	S. ATLANTIC Atlanta, Ga. Baltimore, Md. Charlotte, N.C. Jacksonville, Fla Miami, Fla. Norfolk, Va. Richmond, Va. Savannah, Ga. St. Petersburg, I Tampa, Fla. Washington, De E.S. CENTRAL Birmingham, Al Chattanooga, Te Knoxville, Tenn Mobile, Ala. Montgomery, A	119 477 60 76 Fla. 45 179 C. 200 I. U 831 a. 174 2000. 831 a. 174 2000. 80 50 65 . 151 97 1a. 33	807 89 112 81 83 67 33 30 41 35 129 109 U 555 119 62 52 52 41 94 689	321 40 44 27 37 8 7 41 55 U 179 37 19 15 315 6	121 16 25 7 11 12 4 7 7 23 U 55 7 4 5 4 4 5 4 4 5	36 8 6 1 3 2 - 3 2 1 2 8 U 20 2 2 - 1 2 4 4 5	34 7 3 3 4 1 2 5 U 21 8 1 2 3 4 - 2 5 U 21 8 1 2 3 - 4 - 2 5 U	73 3 14 17 4 8 2 5 6 - 7 7 U 66 15 5 1 3 11 3 13
Erie, Pa.§ Jersey City, N.J. New York City, N.Y. Paterson, N.J. Philadelphia, Pa. Pittsburgh, Pa.§ Reading, Pa. Rochester, N.Y. Schenectady, N.Y. Scranton, Pa.§ Syracuse, N.Y. Trenton, N.J. Utica, N.Y. Yonkers, N.Y.	U 24 328 29 19 134 30 29 78 37 30 U	15 30 775 U 15 217 13 15 97 26 27 55 24 26 U	9 239 U 7 70 9 3 28 4 - 15 11 3 U	1 3 78 0 1 25 4 1 7 - 1 4 2 1 U	1 2 17 9 2 - - 1 1 - - U	- 16 U 1 7 1 - 2 - 3 - 3 - U	1 49 U 3 13 2 1 10 1 2 3 1 3 U	Nashville, Tenn. W.S. CENTRAL Austin, Tex. Baton Rouge, La Corpus Christi, Dallas, Tex. El Paso, Tex. Ft. Worth, Tex. Houston, Tex. Little Rock, Ark. New Orleans, La San Antonio, Te Shreveport, La. Tulsa, Okla.	1,345 79 1. 53 Fex. 51 193 89 103 329 61 . U x. 220 56 111	101 898 54 39 37 123 64 74 189 43 U 158 44 73	35 251 13 9 39 39 18 13 72 9 U 41 5 23	11 117 2 20 4 9 41 3 U 11 5 12	2 44 2 2 1 5 1 6 15 5 U 3 2 2 2	3 35 2 1 2 6 2 1 2 6 2 1 12 1 0 7 1	15 87 4 2 3 13 3 2 25 2 U 17 4 12
E.N. CENTRAL Akron, Ohio Canton, Ohio Chicago, III. Cincinnati, Ohio Cleveland, Ohio Dayton, Ohio Dayton, Ohio Detroit, Mich. Evansville, Ind. Fort Wayne, Ind. Gary, Ind. Grand Rapids, Mi Indianapolis, Ind. Lansing, Mich. Milwaukee, Wis. Peoria, III. South Bend, Ind. Toledo, Ohio Youngstown, Ohi W.N. CENTRAL Des Moines, Iowa Duluth, Minn. Kansas City, Kans Kansas City, Kans Kansas City, Kans St. St. Louis, Mo. St. Paul, Minn. Wichita, Kans.	164 36 116 50 43 74 0 61 773 107 36 . 19 79 48	934 373 31 U 43 91 1238 U 43 13 5 32 2 2 2 41 2 8 2 8 11 5 8 10 5 10 5 8 10 5 10 5 10 5 10 5 10 5 10 5 10 5 10 5	$\begin{array}{c} 5 \\ 9 \\ 0 \\ 30 \\ 32 \\ 6 \\ 1 \\ 9 \\ 7 \\ 40 \\ 6 \\ 12 \\ 8 \\ 8 \\ 20 \\ 11 \\ 132 \\ 17 \\ 5 \\ 3 \\ 16 \\ 5 \\ 30 \\ 14 \\ 211 \end{array}$	79 2 5 U 7 8 14 3 U 2 3 1 2 15 3 5 1 1 4 1 2 5 2 2 4 5 2 7 9 11 5 5	24 1 - U 4 2 3 - 2 - 3 3 - 2 1 - 3 - 2 5 3 7 2 2	37 3 1 U 1 3 7 - U 2 1 - 8 4 - 5 1 - 1 15 1 - 1 2 3 - 4 2 2	8330332701-15133-3242 371-6136-3-	MOUNTAIN Albuquerque, N Boise, Idaho Colo. Springs, C Denver, Colo. Las Vegas, Nev. Ogden, Utah Phoenix, Ariz. Pueblo, Colo. Salt Lake City, U Tucson, Ariz. PACIFIC Berkeley, Calif. Fresno, Calif. Glendale, Calif. Honolulu, Hawa Long Beach, Cal Los Angeles, Ca Pasadena, Calif. Portland, Oreg. Sacramento, Ca San Jose, Calif. San Francisco, C San Jose, Calif. Santa Cruz, Cali Seattle, Wash. Tocma.	37 colo. 69 101 218 27 165 18 17 165 18 17 17 16 16 16 16 16 17 17 16 16 16 16 16 10 10 10 10 10 10 10 10 10 10 10 10 10	621 74 25 46 68 130 98 15 62 85 1,251 11 41 22 69 31 389 21 72 130 95 U 131 28 84 56 71 7,419	$\begin{array}{c} 212\\ 26\\ 6\\ 11\\ 20\\ 5\\ 34\\ 28\\ 280\\ 3\\ 11\\ 6\\ 14\\ 11\\ 7\\ 4\\ 16\\ 228\\ U\\ 31\\ 5\\ 21\\ 11\\ 11\\ 11\\ 6\\ 4\\ 228\\ 1\\ 5\\ 21\\ 11\\ 11\\ 6\\ 2,164\\ \end{array}$	77 9 4 8 12 2 18 - 5 7 105 - 3 1 4 2 27 - 7 18 12 U 12 7 7 - 5 777	35 3 2 1 - 10 2 10 - 4 3 37 - 1 2 11 - 5 4 5 U 4 - 2 2 69	22 1 3 1 8 5 2 2 2 31 2 5 6 U 4 2 2 2 5 6 U 4 2 2 2 2 2 2 2 2 2 2 2 2 2	59 6 - 4 10 9 2 8 1 10 9 125 3 2 1 7 106 2 5 13 9 U 7 6 3 8 3 663

TABLE IV. Deaths in 122 U.S. cities,* week ending August 11, 2001 (32nd Week)

U: Unavailable. -: No reported cases. *Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of ≥100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included. *Pneumonia and influenza.

[®]Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks. [®]Total includes unknown ages.

Contributors to the Production of the MMWR (Weekly)

Weekly Notifiable Disease Morbidity Data and 122 Cities Mortality Data

Samuel L. Groseclose, D.V.M., M.P.H.

State Support Team Robert Fagan Jose Aponte Gerald Jones David Nitschke Scott Noldy Jim Vaughan Carol A. Worsham **CDC Operations Team** Carol M. Knowles Deborah A. Adams Willie J. Anderson Patsy A. Hall Suzette A. Park Felicia J. Perry Pearl Sharp

Informatics

T. Demetri Vacalis, Ph.D.

Michele D. Renshaw

Erica R. Shaver

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to *listserv@listserv.cdc.gov*. The body content should read SUBscribe mmwr-toc. Electronic copy also is available from CDC's World-Wide Web server at http://www.cdc.gov/mmwr or from CDC's file transfer protocol server at ftp://ftp.cdc.gov/pub/Publications/mmwr. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* Series, including material to be considered for publication, to: Editor, *MMWR* Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (888) 232-3228.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Director, Centers for Disease Control and Prevention Jeffrey P. Koplan, M.D., M.P.H.	Director, Epidemiology Program Office Stephen B. Thacker, M.D., M.Sc.	Writers-Editors, <i>MMWR</i> (Weekly) Jill Crane David C. Johnson
Deputy Director for Science and Public Health, Centers for Disease Control and Prevention David W. Fleming, M.D.	Editor, <i>MMWR</i> Series John W. Ward, M.D. Acting Managing Editor, <i>MMWR</i> (Weekly) Teresa F. Rutledge	Desktop Publishing Lynda G. Cupell Morie M. Higgins
☆U.S. Government Printing Office: 2001-633-173/49004 Region IV		